Influenza

Detalhes bibliográficos
Autor(a) principal: Forleo-neto, Eduardo
Data de Publicação: 2003
Outros Autores: Halker, Elisa, Santos, Verônica Jorge, Paiva, Terezinha Maria, Toniolo Neto, João [UNIFESP]
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0037-86822003000200011
http://repositorio.unifesp.br/handle/11600/1687
Resumo: Influenza (flu) is an acute contagious viral infection characterized by inflammation of the respiratory tract that every winter affects more than 100 million people in Europe, Japan and the United States of America, also being responsible for several thousand of excess deaths (data from the United States reveal between 20,000 to 40,000 excess deaths annually). The Mixovirus influenzae is the agent that causes influenza, commonly called flu. There are 3 types of influenza virus: A, B, C, and only types A and B are perceived to be clinically relevant in humans. Due to the segmented nature of its genetic material, the influenza virus is highly mutagenic, causing frequent insertion of new antigenic strains into the community, against which the population presents no immunity. Presently, there are few options for the control of influenza and annual immunization is the most effective means to prevent disease and its complications. In Brazil, according to data collected by the VigiGripe's Project - linked to the Federal University of São Paulo -, circulation of the influenza virus also has a seasonal pattern, with peak activity occurring between May and September. Yearly vaccination is, therefore, best indicated on March and April. Currently, there are four medications available for the treatment of influenza viruses: amantadine and rimantadine, and two second generation pharmaceutical products, the neuraminidase inhibitors, oseltamivir and zanamivir. The latter two drugs have set the stage for a new approach to the management and control of influenza infections.
id UFSP_d933ab1911a23bc2ece573b9623537d7
oai_identifier_str oai:repositorio.unifesp.br/:11600/1687
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling InfluenzaInfluenzaInfluenzaFluEpidemiologyVaccineTreatmentInfluenzaGripeEpidemiologiaVacinaTratamentoInfluenza (flu) is an acute contagious viral infection characterized by inflammation of the respiratory tract that every winter affects more than 100 million people in Europe, Japan and the United States of America, also being responsible for several thousand of excess deaths (data from the United States reveal between 20,000 to 40,000 excess deaths annually). The Mixovirus influenzae is the agent that causes influenza, commonly called flu. There are 3 types of influenza virus: A, B, C, and only types A and B are perceived to be clinically relevant in humans. Due to the segmented nature of its genetic material, the influenza virus is highly mutagenic, causing frequent insertion of new antigenic strains into the community, against which the population presents no immunity. Presently, there are few options for the control of influenza and annual immunization is the most effective means to prevent disease and its complications. In Brazil, according to data collected by the VigiGripe's Project - linked to the Federal University of São Paulo -, circulation of the influenza virus also has a seasonal pattern, with peak activity occurring between May and September. Yearly vaccination is, therefore, best indicated on March and April. Currently, there are four medications available for the treatment of influenza viruses: amantadine and rimantadine, and two second generation pharmaceutical products, the neuraminidase inhibitors, oseltamivir and zanamivir. The latter two drugs have set the stage for a new approach to the management and control of influenza infections.A influenza (gripe) é doença infecciosa aguda de origem viral que acomete o trato respiratório e a cada inverno atinge mais de 100 milhões de pessoas na Europa, Japão e Estados Unidos, causando anualmente a morte de cerca de 20 a 40 mil pessoas somente neste último país. O agente etiológico é o Myxovirus influenzae, ou vírus da gripe. Este subdivide-se nos tipos A, B e C, sendo que apenas os do tipo A e B apresentam relevância clínica em humanos. O vírus influenza apresenta altas taxas de mutação, o que resulta freqüentemente na inserção de novas variantes virais na comunidade, para as quais a população não apresenta imunidade. São poucas as opções disponíveis para o controle da influenza. Dentre essas, a vacinação constitui a forma mais eficaz para o controle da doença e de suas complicações. Em função das mutações que ocorrem naturalmente no vírus influenza, recomenda-se que a vacinação seja realizada anualmente. No Brasil, segundo dados obtidos pelo Projeto VigiGripe - ligado à Universidade Federal de São Paulo (UNIFESP) -, verifica-se que a influenza apresenta pico de atividade entre os meses de maio e setembro. Assim, a época mais indicada para a vacinação corresponde aos meses de março e abril. Para o tratamento específico da influenza estão disponíveis quatro medicamentos antivirais: os fármacos clássicos amantadina e rimantidina e os antivirais de segunda geração oseltamivir e zanamivir. Os últimos, acrescentam alternativas para o tratamento da influenza e ampliam as opções disponíveis para o seu controle.Grupo de Vigilância Epidemiológica da Gripe Divisão VigiVírusInstituto Adolfo Lutz de São Paulo Seção de Vírus RespiratóriosUniversidade Federal de São Paulo (UNIFESP)UNIFESP, EPM, Sao Paulo, BrazilSciELOSociedade Brasileira de Medicina Tropical - SBMTGrupo de Vigilância Epidemiológica da Gripe Divisão VigiVírusInstituto Adolfo Lutz de São Paulo Seção de Vírus RespiratóriosUniversidade Federal de São Paulo (UNIFESP)Forleo-neto, EduardoHalker, ElisaSantos, Verônica JorgePaiva, Terezinha MariaToniolo Neto, João [UNIFESP]2015-06-14T13:29:58Z2015-06-14T13:29:58Z2003-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion267-274application/pdfhttp://dx.doi.org/10.1590/S0037-86822003000200011Revista da Sociedade Brasileira de Medicina Tropical. Sociedade Brasileira de Medicina Tropical - SBMT, v. 36, n. 2, p. 267-274, 2003.10.1590/S0037-86822003000200011S0037-86822003000200011.pdf0037-8682S0037-86822003000200011http://repositorio.unifesp.br/handle/11600/1687porRevista da Sociedade Brasileira de Medicina Tropicalinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-10-14T13:51:18Zoai:repositorio.unifesp.br/:11600/1687Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-10-14T13:51:18Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Influenza
Influenza
title Influenza
spellingShingle Influenza
Forleo-neto, Eduardo
Influenza
Flu
Epidemiology
Vaccine
Treatment
Influenza
Gripe
Epidemiologia
Vacina
Tratamento
title_short Influenza
title_full Influenza
title_fullStr Influenza
title_full_unstemmed Influenza
title_sort Influenza
author Forleo-neto, Eduardo
author_facet Forleo-neto, Eduardo
Halker, Elisa
Santos, Verônica Jorge
Paiva, Terezinha Maria
Toniolo Neto, João [UNIFESP]
author_role author
author2 Halker, Elisa
Santos, Verônica Jorge
Paiva, Terezinha Maria
Toniolo Neto, João [UNIFESP]
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Grupo de Vigilância Epidemiológica da Gripe Divisão VigiVírus
Instituto Adolfo Lutz de São Paulo Seção de Vírus Respiratórios
Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Forleo-neto, Eduardo
Halker, Elisa
Santos, Verônica Jorge
Paiva, Terezinha Maria
Toniolo Neto, João [UNIFESP]
dc.subject.por.fl_str_mv Influenza
Flu
Epidemiology
Vaccine
Treatment
Influenza
Gripe
Epidemiologia
Vacina
Tratamento
topic Influenza
Flu
Epidemiology
Vaccine
Treatment
Influenza
Gripe
Epidemiologia
Vacina
Tratamento
description Influenza (flu) is an acute contagious viral infection characterized by inflammation of the respiratory tract that every winter affects more than 100 million people in Europe, Japan and the United States of America, also being responsible for several thousand of excess deaths (data from the United States reveal between 20,000 to 40,000 excess deaths annually). The Mixovirus influenzae is the agent that causes influenza, commonly called flu. There are 3 types of influenza virus: A, B, C, and only types A and B are perceived to be clinically relevant in humans. Due to the segmented nature of its genetic material, the influenza virus is highly mutagenic, causing frequent insertion of new antigenic strains into the community, against which the population presents no immunity. Presently, there are few options for the control of influenza and annual immunization is the most effective means to prevent disease and its complications. In Brazil, according to data collected by the VigiGripe's Project - linked to the Federal University of São Paulo -, circulation of the influenza virus also has a seasonal pattern, with peak activity occurring between May and September. Yearly vaccination is, therefore, best indicated on March and April. Currently, there are four medications available for the treatment of influenza viruses: amantadine and rimantadine, and two second generation pharmaceutical products, the neuraminidase inhibitors, oseltamivir and zanamivir. The latter two drugs have set the stage for a new approach to the management and control of influenza infections.
publishDate 2003
dc.date.none.fl_str_mv 2003-04-01
2015-06-14T13:29:58Z
2015-06-14T13:29:58Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0037-86822003000200011
Revista da Sociedade Brasileira de Medicina Tropical. Sociedade Brasileira de Medicina Tropical - SBMT, v. 36, n. 2, p. 267-274, 2003.
10.1590/S0037-86822003000200011
S0037-86822003000200011.pdf
0037-8682
S0037-86822003000200011
http://repositorio.unifesp.br/handle/11600/1687
url http://dx.doi.org/10.1590/S0037-86822003000200011
http://repositorio.unifesp.br/handle/11600/1687
identifier_str_mv Revista da Sociedade Brasileira de Medicina Tropical. Sociedade Brasileira de Medicina Tropical - SBMT, v. 36, n. 2, p. 267-274, 2003.
10.1590/S0037-86822003000200011
S0037-86822003000200011.pdf
0037-8682
S0037-86822003000200011
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Revista da Sociedade Brasileira de Medicina Tropical
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 267-274
application/pdf
dc.publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical - SBMT
publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical - SBMT
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268455775371264